STAT

FEBRUARY 26, 2024

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound , they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease. A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunctio

Diabetes 319

Diabetes Compounding Drug Development 319

ALiEM - Pharm Pearls

FEBRUARY 26, 2024

An 18-day-old male presented for a rash on his face for two days. The patient was born via spontaneous vaginal delivery full term without complications to a mom who has a history of genital HSV but without active lesions at delivery and on acyclovir. The patient presented with a vesicular rash on his face including around his eyes. He had conjunctival discharge noted by mom.

192

192

STAT

FEBRUARY 26, 2024

Early last year, MD Anderson Cancer Center leadership had a problem on their hands: a contentious dispute between one of its most powerful researchers and a junior scientist over authorship, credit, and charges of verbal abuse. High-ranking officials at the cancer center tried — and failed — to resolve the feud, and documents obtained by STAT shed new light on the deep divisions at the heart of this case.

Documentation 319

Documentation 319

PharmaVoice

FEBRUARY 26, 2024

GLP-1 drugs indications could expand as research shows potential benefits in treating MASH, where pharma has previously failed in the past.

147

147

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

FEBRUARY 26, 2024

After the recent nitrogen gas execution in Alabama of Kenneth Smith, state Attorney General Steve Marshall said that nitrogen gas “was intended to be — and has now proved to be — an effective and humane method of execution.” It is hard to imagine a statement so obviously disconnected from facts. Eyewitness accounts described Smith’s death as a harrowing experience of dry heaving, thrashing, straining against leather straps, seizures, and terror.

306

306

The Pharmacist

FEBRUARY 26, 2024

Nearly 400,000 vape kits are set to be sent to smokers in England under the government’s swap-to-stop scheme, our sister title Healthcare Leader has exclusively revealed. At least four integrated care boards (ICBs) and more than 80 localities have expressed interest in the scheme with 379,562 ‘vape starter kits’ requested as of February 2024, data […] The post Nearly 400,000 vape kits to be sent to smokers appeared first on The Pharmacist.

133

133

PharmaVoice

FEBRUARY 26, 2024

Rare disease treatments, drug shortages, a market monopoly and march-in rights all play a role in the story of newly revived litigation against Sanofi’s Genzyme.

100

100

STAT

FEBRUARY 26, 2024

The Aztecs called it teonanácatl, or “flesh of the Gods.” Some who ate the intoxicating mushroom “saw themselves dying in a vision and wept,” according to an account by a 16th-century Franciscan friar. “Others saw themselves being eaten by a wild beast; others imagined that they were capturing prisoners in battle, that they were rich.

Documentation 231

Documentation 231

pharmaphorum

FEBRUARY 26, 2024

Sanofi gets a win for its oral BTK inhibitor rilzabrutinib in chronic hive disorder CSU, setting up a phase 3 programme as it chases after Novartis’ remibrutinib in this indication.

106

106

STAT

FEBRUARY 26, 2024

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because — you know what we are going to say — that oh-so familiar routine of online meetings, endless calls and deadlines has returned. But what can you do? The world, such as it is, continues to spin. So let us be optimistic and convince ourselves we can nudge it in a better direction with a cup of stimulation.

Drug Pricing 225

Drug Pricing 225

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Fuld & Company Blog

FEBRUARY 26, 2024

Last week, Shell made a move that looked very much like a major nail in the coffin of the hydrogen passenger car market. In October 2023, Shell quietly shut down its three UK hydrogen filling stations for passenger cars. Following this, last week, it did the same in California. Originally planning to establish 48 stations across the state, Shell scrapped these plans last year and announced the closure of all five passenger car stations, while maintaining its three heavy-duty hydrogen stations

105

105

STAT

FEBRUARY 26, 2024

R1 RCM, a large publicly traded technology company that helps hospitals and physicians collect money from insurers and patients, may be going private. Private equity firm New Mountain Capital has offered to purchase R1 for $13.75 per share, or roughly $5.8 billion in cash, according to new financial disclosures filed Monday. New Mountain Capital is R1’s second-largest investor, owning nearly one-third of the company’s shares.

Hospitals 206

Hospitals 206

BioPharma Dive

FEBRUARY 26, 2024

Zealand shares rose by more than one-third on the data, which provide further evidence so-called incretin drugs could help treat people with the liver disease.

112

112

STAT

FEBRUARY 26, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with a look at some renewed interest in a yesteryear biotech craze, news of an FDA flex, and a dive into the science of vaccinology.

Drug Pricing 206

Drug Pricing Drug Development Vaccines 206

Drug Patent Watch

FEBRUARY 26, 2024

Switching pharmaceutical excipients, the inactive components used in drug formulations, can have significant implications for both production costs and market appeal. These components, while not contributing directly to the therapeutic… The post Cost-Cut Without Compromise: Navigating Excipient Switching in Pharma appeared first on DrugPatentWatch - Make Better Decisions.

105

105

pharmaphorum

FEBRUARY 26, 2024

GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea.

102

102

Pharmaceutical Technology

FEBRUARY 26, 2024

Bayer’s oral tyrosine kinase inhibitor is currently in a Phase I trial estimated to enrol 460 patients.

132

132

Express Pharma

FEBRUARY 26, 2024

Plazomicin is a new Intravenous (IV) aminoglycoside indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis Cipla receives approval from the Central Drugs Standard Control Organization (CDSCO) to market the novel antibiotic plazomicin in India. Plazomicin is a new Intravenous (IV) aminoglycoside indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis.

Hospitals 97

Hospitals 97

Pharmaceutical Technology

FEBRUARY 26, 2024

Merck's KEYTRUDA has received a positive opinion from the EMA CHMP for use in combination with chemotherapy for non-small cell lung cancer.

Chemotherapy 104

Chemotherapy 104

Express Pharma

FEBRUARY 26, 2024

The site will expand the company’s global drug development and IT & digital capabilities Bristol Myers Squibb has announced the official opening of a new facility in Hyderabad. The site will expand the company’s global drug development and IT & digital capabilities and is expected to be home to over 1,500 employees. The company has invested over $100 million in the creation of this cutting-edge facility.

Drug Development 94

Drug Development 94

European Pharmaceutical Review

FEBRUARY 26, 2024

[The Phase II trial showed that] up to 83.0 percent of adults given survodutide (BI 456906) achieved a statistically significant improvement of the liver disease metabolic dysfunction-associated steatohepatitis (MASH)” Up to 83.0 percent of adults given survodutide (BI 456906) achieved a statistically significant improvement of the liver disease metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2 percent) in a Phase II trial.

Diabetes 92

Diabetes 92

Express Pharma

FEBRUARY 26, 2024

The 21 st edition of BioAsia which has been much talked about summit in the beginning of the year has been attracting both domestic and international stakeholders in life-sciences and healthcare industry Around 200 delegates comprising both international delegates and Indian companies were taken in for a guided tour of the Genome Valley in Hyderabad in two groups on the inaugural day of BioAsia 2024.

92

92

pharmaphorum

FEBRUARY 26, 2024

AstraZeneca has moved a step closer to EU approval of oral Factor D inhibitor danicopan in the EU, after the EMA’s human medicines committee, the CHMP, backed the drug as a treatment for residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria (PNH).

91

91

Express Pharma

FEBRUARY 26, 2024

The partnership will build upon existing manufacturing capacity for the vaccine at Takeda’s facility in Singen, Germany and Takeda’s long-term partnership with IDT Biologika GmbH Takeda and Biological E. Limited (BE) has announced a strategic partnership to accelerate access to QDENGA▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs).

Vaccines 91

Vaccines Packaging 91

European Pharmaceutical Review

FEBRUARY 26, 2024

At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. The committee adopted positive opinions for two vaccines intended for active immunisation against the H5N1 subtype of influenza A virus: Celldemic (zoonotic influenza vaccine (H5N1)(surface antigen, inactivated, adjuvanted, prepared in cell cultures)), is intended for immunisation during outbre

Generic Medicine 90

Generic Medicine Vaccines Pharmaceutical Companies Pharmaceutical Companies 90

Pharma Times

FEBRUARY 26, 2024

Every year, tuberculosis, malaria and HIV cause over five million deaths worldwide

123

123

pharmaphorum

FEBRUARY 26, 2024

Digital health company Akili expands beyond the US as partner Shionogi files for approval for its ADHD digital therapeutic (DTx) in Japan

101

101

Pharma Times

FEBRUARY 26, 2024

Results from the study could also be used for other forms of cancer and diseases

122

122

Express Pharma

FEBRUARY 26, 2024

The letter states that the said scheme may be similar to that which is for upgrading for WHO GMP The Federation of Pharma Entrepreneurs (FOPE) has written a letter to the Department of Pharmaceuticals requesting a new scheme for funding to MSME to upgrade the manufacturing facilities to meet the requirement of revised Schedule M The letter states that the said scheme may be similar to that which is for upgrading for WHO GMP.

Documentation 83

Documentation 83

Pharmaceutical Technology

FEBRUARY 26, 2024

SK bioscience has achieved a significant milestone with its typhoid conjugate vaccine, SKYTyphoid, receiving WHO prequalification.

Vaccines 97

Vaccines 97

pharmaphorum

FEBRUARY 26, 2024

Boehringer Ingelheim and Zealand Pharma report stellar top-line results for GLP-1/glucagon agonist survodutide in liver disease MASH.

95

95

The Pharmacist

FEBRUARY 26, 2024

Negotiations on the next Community Pharmacy Contractual Framework have begun, but Community Pharmacy England (CPE) has warned the sector to avoid having too high expectations of its outcome. Speaking to delegates at the 2024 Sigma Conference by live video link, Janet Morrison, CPE chief executive, confirmed the negotiator had recently met with the government for […] The post Don’t expect ‘revolutionary’ contract, says CPE as negotiations begin appeared first on The Pharmacist.

Community Pharmacies 84

Community Pharmacies 84

World Pharma News

FEBRUARY 26, 2024

Lung cancer is not the most common form of cancer, but it is by far the deadliest. Despite treatments such as surgery, radiation therapy and chemotherapy, only about a quarter of all people with the disease will live more than five years after diagnosis, and lung cancer kills more than 1.8 million people worldwide each year, according to the World Health Organization.

Chemotherapy 84

Chemotherapy 84

The Pharmacist

FEBRUARY 26, 2024

Community Pharmacy England (CPE) chief executive Janet Morrison has expressed concerns regarding the minimum number of consultations pharmacies will be required to deliver for the Pharmacy First service from October this year. In order to receive a fixed payment of £1,000 per month, Pharmacy First providers in England need to deliver a minimum number of […] The post Pharmacy First minimum consultation numbers a ‘major concern’ for CPE appeared first on The Pharmacist.

Community Pharmacies 83

Community Pharmacies 83

EMCrit Project

FEBRUARY 26, 2024

Do you still need to worry about contrast in patients with tenuous renal function? EMCrit Project by Scott Weingart, MD FCCM.

89

89